Cellectis CLLS 深 沪
已收盘 07-31 16:00:00 美东时间
2.75
-0.100
-3.51%
华盛通- 最 高2.85
- 今 开2.85
- 成交量 1.27万股
- 最 低 2.67
- 昨 收 2.85
- 总市值 2.77亿
- 52周最高 5.4796
- 市盈率 静 --
- 换手率 0.01%
- 52周最低 2.481
- 委 比 88.36%
- 总股本 1.01亿
- 历史最高 50.00
- 量 比 1.13
- 振 幅 6.32%
- 历史最低 0.9628
- 每 手 1
- 风险率 0.65%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Cellectis Secures FDA Regenerative Medicine Advanced Therapy Designation For lasme-cel, CD22-Targeting Allogeneic CAR-T Cell Therapy Product Candidate, For Treatment Of r/r B-ALL
Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today announced that the U.S. Food and Drug
06-10 04:32
美股大行评级 | 瑞穗上调戴尔目标价至350美元！华尔街齐上调迈威尔科技目标价；瑞银大幅上调Snowflake目标价
瑞穗上调戴尔目标价至350美元！华尔街齐上调迈威尔科技目标价；瑞银大幅上调Snowflake目标价
05-29 18:09
Barclays Initiates Coverage On Cellectis with Overweight Rating, Announces Price Target of $9
Barclays analyst Lukas Shumway initiates coverage on Cellectis (NASDAQ:CLLS) with a Overweight rating and announces Price Target of $9.
05-28 21:37
Cellectis To Present Phase 1 CAR-T Data For Lasme-cel And Eti-cel At EHA 2026, Highlighting Early Safety, Response Signals And Ongoing Pivotal Programs
Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today announced upcoming presentations on the
05-12 21:34
Cellectis Q1 Adj. EPS $(0.16) Beats $(0.27) Estimate, Sales $7.548M Miss $12.267M Estimate
Cellectis (NASDAQ:CLLS) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.27) by 40.74 percent. This is a 5.88 percent increase over losses of $(0.17) per share from the same
05-12 04:32
Earnings Scheduled For May 11, 2026
Companies Reporting Before The Bell • United Parks & Resorts (NYSE:PRKS) is...
05-11 19:11
Cellectis Presents New Research On TALE-Based Epigenetic Editing Approach At ASGCT Annual Meeting
Cellectis (the "Company") (NASDAQ:CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today presents new research on a TALE-based
04-28 04:33
美股大行评级 | 小摩上调Bloom Energy目标价从166美元升至231美元；目标价28美元！大摩、高盛等多家机构首予Janus Living(JAN)超配评级
今日重点评级关注：Ascendiant Capital：维持Banzai International"买入"评级，目标价从23美元升至24美元；Ascendiant Capital：维持Synergy CHC Corp."买入"评级，目标价从5美元升至5.5美元
04-15 11:31
Citizens Reiterates Market Outperform on Cellectis, Maintains $8 Price Target
Citizens analyst Silvan Turkcan reiterates Cellectis (NASDAQ:CLLS) with a Market Outperform and maintains $8 price target.
04-14 20:40
Allogene Therapeutics Hits 52-Week High - Here's Why
Allogene's ALPHA3 trial shows strong MRD clearance and ctDNA reduction, signaling potential to delay relapse in lymphoma patients.
04-14 00:59
